# AVITA Medical share price today (AVITA Medical, Inc., RCEL)

> AVITA Medical, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. RCEL · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/rcel

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $15.33 (+296.1% in a year)
- Revenue (Jun 2026): $21.7 M (+17.8% on a year ago)
- Profit (Jun 2026): −$7.7 M
- Operating margin: −31.6% (+28.9 points on a year ago)
- ROE: 292%, FY25
- ROIC: −84.1%, against a 15.1% cost of capital: −99.2 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the AVITA Medical share price today? AVITA Medical, Inc.'s share price was $15.33 at the close on 3 November 2026. That is 129.8% above its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $16, and at that close it sat 97% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 14 weeks in a row. Over the last 1 year the share price moved +169% while the S&P 500 moved +21%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does AVITA Medical pay? AVITA Medical, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is AVITA Medical on? AVITA Medical is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is AVITA Medical profitable? AVITA Medical, Inc. posted a net loss of $7.7 M in the Jun 2026 quarter. The full FY25 year was a loss of $48.6 M. That loss is 35.3% of the quarter's revenue. The same quarter a year earlier lost $9.9 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does AVITA Medical make, and is it growing? AVITA Medical, Inc. reported $21.7 M of revenue in the Jun 2026 quarter, +17.8% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown 25.1% a year on average. The last full year, FY25, came in at $71.6 M. The last four reported quarters add to $75.6 M. FY25 revenue was $71.6 M, +11.5% on the year before. Recent pace: the last four quarters grew +1.2% on average, against 25.1% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +1.0%, against +18.2% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does AVITA Medical keep? AVITA Medical, Inc.'s operating margin was −31.6% in the Jun 2026 quarter, 28.9 percentage points higher than the same quarter a year ago. Across 6 years it has been between −90.8% and −59.4%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +28.9 percentage points on the year while gross margin changed +0.7 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is AVITA Medical's profit turning into cash? AVITA Medical, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $31.2 M of cash, against −$48.6 M of profit. After $1.0 M of spending on assets, free cash was −$32.2 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does AVITA Medical's cash go? AVITA Medical, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $11.6 M on assets over the last 3 years. Averaged over those years that is 5.4% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $11.6 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is AVITA Medical's P/E ratio, and how does it compare with its own history? AVITA Medical, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values AVITA Medical, Inc. at 6.6× its FY25 revenue of $71.6 M. The P/E comes back here once profit turns positive. ## Is the AVITA Medical business getting better or worse? AVITA Medical, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does AVITA Medical earn on its capital? AVITA Medical, Inc. earned a ROE of 292% in FY25. That is up from a low of −1,375% in FY24. Its return on capital used (ROIC) is 99.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −67.8% net margin and 1.27× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −67.8% net margin × 1.27× asset turnover × −3.39× leverage (assets divided by equity) ≈ 291.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −84.1% − 15.1% = −99.2 percentage points. The 15.1% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does AVITA Medical have too much debt? AVITA Medical, Inc.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from 0.00 in FY21 to −2.77 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the AVITA Medical shareholding pattern? We have no ownership or short-position figures for AVITA Medical, Inc., so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 8.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is AVITA Medical from balance-sheet trouble? For AVITA Medical, Inc., the Z-score is −13.31. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −13.31 is inside the danger zone, so the balance sheet is a real risk. ## How does AVITA Medical rank in its industry? There is no score against its industry: AVITA Medical, Inc. is not among the largest members shown in this industry comparison for Medical Devices. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is AVITA Medical compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to AVITA Medical in size? AVITA Medical is the 54th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Tactile Systems Technology, Inc., Sight Sciences, Inc. and Delcath Systems, Inc. Just below it: Cerus Corporation, Senseonics Holdings, Inc. and SS Innovations International, Inc. ### Medical Devices companies close in size

1. [Tactile Systems Technology, Inc.](https://www.sectoralpha.in/us/stocks/tcmd) $561 million
2. [Sight Sciences, Inc.](https://www.sectoralpha.in/us/stocks/sght) $519 million
3. [Delcath Systems, Inc.](https://www.sectoralpha.in/us/stocks/dcth) $500 million
4. AVITA Medical, Inc. $474 million
5. [Cerus Corporation](https://www.sectoralpha.in/us/stocks/cers) $472 million
6. [Senseonics Holdings, Inc.](https://www.sectoralpha.in/us/stocks/sens) $468 million
7. [SS Innovations International, Inc.](https://www.sectoralpha.in/us/stocks/ssii) $467 million

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Evolent Health, Inc.](https://www.sectoralpha.in/us/stocks/evh) $486 million · Health Information Services
2. [Evolus, Inc.](https://www.sectoralpha.in/us/stocks/eols) $485 million · Drug Manufacturers - Specialty & Generic
3. AVITA Medical, Inc. $484 million
4. [American Bitcoin Corp.](https://www.sectoralpha.in/us/stocks/abtc) $484 million · Capital Markets
5. [Gyre Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/gyre) $483 million · Biotechnology

## What else do people ask about AVITA Medical? ### What were AVITA Medical's latest quarterly results? AVITA Medical, Inc. reported revenue of $21.7 M and a net loss of $7.7 M for the Jun 2026 quarter. Earnings per share were −$0.25. The operating margin was −31.6%, 28.9 percentage points higher than a year earlier (as of 3 November 2026). ### What is AVITA Medical's market cap? AVITA Medical, Inc.'s market capitalisation is $474 M at a stock price of $15.33. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is AVITA Medical performing? AVITA Medical, Inc.'s latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 14 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will AVITA Medical's stock price go up? This page does not forecast AVITA Medical, Inc.'s stock price. What it shows instead: the stock price is $15.33. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is AVITA Medical in its business cycle? AVITA Medical, Inc.'s FY25 operating margin was −59.4%, against a 6-year range of −90.8% to −59.4%: the middle of its own range, neither a peak nor a low. The latest quarter was −31.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the AVITA Medical story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is AVITA Medical a stock worth studying right now? What the numbers show: AVITA Medical, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.